BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Canadian Securities Exchange (CSE) Level 1 and 2

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $738.72 only $295.49

ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.69
0.27%
US Tech 100
20,239.20
-0.65%
S&P 500
5,998.74
-0.38%
US Dollar vs CAD
1.40168
-0.07%
Bitcoin
96,296.09
0.33%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Marker Therapeutics Inc (MRKR) Share Price

Marker Therapeutics Inc

Marker Therapeutics Inc (MRKR)

NASDAQ
3.19
-0.07
(-2.15%)
Closed November 27 3:00PM
Delayed by 15 minutes
3.42
0.23
(7.21%)
After Hours: 5:55PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
3.42
Bid
3.15
Ask
3.84
Volume
12,204
3.1263 Day's Range 3.49
2.4377 52 Week Range 6.1568
Market Cap
30.516M
Previous Close
3.26
Open
3.26
Last Trade
6
@
3.38
Last Trade Time
Financial Volume
US$ 39,810
VWAP
3.262
Average Volume (3m)
36,978
Shares Outstanding
8,922,695
Dividend Yield
-
PE Ratio
-3.73
Earnings Per Share (EPS)
-0.92
Revenue
3.31M
Net Profit
-8.24M

About Marker Therapeutics Inc

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops prod... Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. Show more

Sector
Pharmaceutical Preparations
Industry
Business Services, Nec
Website
www.markertherapeutics.com
Headquarters
Wilmington, Delaware, USA
Founded
2006
Marker Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MRKR. The last closing price for Marker Therapeutics was US$3.26. Over the last year, Marker Therapeutics shares have traded in a share price range of US$ 2.4377 to US$ 6.1568.

Marker Therapeutics currently has 8,922,695 shares outstanding. The market capitalization of Marker Therapeutics is US$29.09 million. Marker Therapeutics has a price to earnings ratio (PE ratio) of -3.73.

Ask ADVFN Intelligence (AI)

MRKR Latest News

More News

Form S-3 - Registration statement under Securities Act of 1933

4 hours ago
Edgar (US Regulatory)

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

HOUSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies...

November 26 2024
GlobeNewswire Inc.

Form 8-K - Current report

November 14 2024
Edgar (US Regulatory)

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies...

November 14 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 14 2024
Edgar (US Regulatory)

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing...

August 28 2024
GlobeNewswire Inc.

Form 8-K - Current report

August 14 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 14 2024
Edgar (US Regulatory)

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of...

August 14 2024
GlobeNewswire Inc.

Form 8-K - Current report

August 12 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.195.882352941183.233.62.9101344063.2002712CS
4-0.58-14.544.4462.8205294073.50751521CS
120.278.571428571433.155.022.4377369783.37901779CS
26-0.72-17.39130434784.145.992.4377313673.79815742CS
520.7126.19926199262.716.15682.4377402094.25718622CS
156-9.08-72.6412.512.60.67063998664.57724675CS
260-29.58-89.63636363643337.70.670660677316.02833608CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VCIGVCI Global Ltd
US$ 4.1092
(129.56%)
257.18M
IDAIT Stamp Inc
US$ 0.835
(128.77%)
369.69M
WAITop KingWin Ltd
US$ 0.43
(79.17%)
121.91M
HWHHWH International Inc
US$ 0.918
(62.48%)
32.06M
PROCProcaps Group SA
US$ 2.149
(58.01%)
210.26k
PGHLPrimega Group Holdings Ltd
US$ 1.6455
(-98.47%)
43.2M
OTLKOutlook Therapeutics Inc
US$ 1.695
(-65.34%)
61.98M
IMGCIMG Inc
US$ 0.8831
(-44.81%)
5.22M
KDLYKindly MD Inc
US$ 1.075
(-43.12%)
3.54M
HAOHaoxi Health Technology Ltd
US$ 0.13
(-36.59%)
36.86M
IDAIT Stamp Inc
US$ 0.835
(128.77%)
374.38M
VCIGVCI Global Ltd
US$ 4.1092
(129.56%)
257.57M
NVDANVIDIA Corporation
US$ 135.34
(-1.15%)
226.41M
WAITop KingWin Ltd
US$ 0.43
(79.17%)
121.92M
MARAMARA Holdings Inc
US$ 26.915
(7.79%)
87.94M

MRKR Discussion

View Posts
Phantom Lord Phantom Lord 3 hours ago
They aren't meeting with retail investors. They are looking to meet with investment firms for a future capital raise.
👍️0
CorsairNavigator20 CorsairNavigator20 5 hours ago
According to the jmp conference Dr Vera is going to be talking to registered investors. Anybody on this site going to have a chat with him
👍️0
learningcurve2020 learningcurve2020 11 hours ago
Never be embarrased for biotech management because they always seem to do just fine for themselves.  It's the silent shareholders who deserve to be embarrassed.  
👍️0
Buckboard Buckboard 1 day ago
Thanks
👍️0
CorsairNavigator20 CorsairNavigator20 1 day ago
One would hope not. I could feel embarrassed for him if that is the case. Waiting to see if he will talk about trends in the data.
👍️ 2
learningcurve2020 learningcurve2020 1 day ago
Hallelujah!  Better not be just three trial patients.  
👍️0
jobynimble jobynimble 1 day ago
https://www.globenewswire.com/news-release/2024/11/26/2987657/0/en/Marker-Therapeutics-to-Present-at-the-Citizens-JMP-Hematology-and-Oncology-Summit.html

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
November 26, 2024 11:00 ET
| Source: Marker Therapeutics

HOUSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the Citizens JMP Hematology and Oncology Summit. This investor event will be held virtually on December 2, 2024.

Dr. Vera will present an overview of Marker’s technology and clinical developments on Monday, December 2, 2024, at 11 AM EST.

Click above link for full release…
👍️ 1
ShadowHaven59 ShadowHaven59 1 day ago
Could it be the conference on Monday, why they were taking extra time to prepare the final data? Hopefully they release news on Monday. let’s see a run up on the stock price before the conference.
👍️ 2
learningcurve2020 learningcurve2020 1 day ago
Yup, Vera is still on their board.  Guess he couldn't sell a Marker takeover.  Anyone here ever ask him about it? 

https://www.allovir.com/our-people/juan-f-vera-md
👍️0
ShadowHaven59 ShadowHaven59 2 days ago
The company responded to me on 11/12 and 11/15 hopefully they’re trying to get better. I just like that the same information the analyst received, so did I.
👍️0
learningcurve2020 learningcurve2020 2 days ago
There's that "Runway" language again. AlloVir cut their staff and are using their remaining $100M for a new drug in a new indication instead of simply taking over Marker where they could've put their off the shelf T-cell knowledge to good use.  

>>The merged company is expected to have $100 million in the bank, which is set to pave a cash runway into the final months of 2026. AlloVir’s stockholders will own 25.05% of the resulting entity, with Kalaris’ stockholders owning the other 74.95%.



https://www.fiercebiotech.com/biotech/struggling-allovir-finds-new-identity-merging-eye-disease-biotech
👍️0
learningcurve2020 learningcurve2020 2 days ago
Thanks. What were the dates on those emails?...How much time has gone by?
👍️0
learningcurve2020 learningcurve2020 2 days ago
Not important, I guess.  LOL
👍️0
ShadowHaven59 ShadowHaven59 3 days ago
Yes, no problem, the first email I previously spoke about was the lack of transparency from the company and keeping the shareholders in the dark about the data from all the trials. The company responded agreeing with me and said they will work on trying to be more transparent and also keeping the shareholders more up-to-date. the company said they are currently working a comprehensive data update and are looking forward to sharing this information with our investors after completion of some remaining details. we appreciate your patience. this was the same information that the company told the analyst. The second email was just basically asking the CEO and upper management to buy shares in the open market if they believe in the company and the platform. Maria responded by thanking me and she said that she will forward the message to upper management.
👍️0
CorsairNavigator20 CorsairNavigator20 3 days ago
Do you care to share your discussions with them
👍️ 1
ShadowHaven59 ShadowHaven59 4 days ago
I’ve noticed a change in the frequency of responses from the company lately. in the last two years, I have never received a response, but in the last two months, I have received a response from my last two emails to the company, not sure it means anything, but I thought I would just post it in the chat room anyway. thank you everyone for your valuable information.
👍️0
learningcurve2020 learningcurve2020 4 days ago
Have you ever asked them why they don't address their shareholders on quarterly calls /Q&A but instead seem to rely on you to communicate? 
👍️0
Phantom Lord Phantom Lord 5 days ago
It's grant money.
👍️0
microcapbiotech microcapbiotech 5 days ago
Interesting cancer article. "Groundbreaking clinical trial cures cancer in 100% of patients."
https://www.msn.com/en-us/health/other/groundbreaking-clinical-trial-cures-cancer-in-100-of-patients/ar-AA1uqFJg?ocid=msedgdhp&pc=U531&cvid=be9d60cda7174620ee78a7879d0f9022&ei=45
Which brings up a question that I asked about 2 years ago, WHY doesn't MRKR use their Multi TAA, (now called MAR) ALONG WITH a checkpoint inhibitor that blocks the PD-1 protein on T-cells? Never got an answer to that.
👍️ 1
Flyingj Flyingj 5 days ago
Anybody know where the 1.92 million in sales came from this quarter? Is part of it right to try patients
👍️0
Phantom Lord Phantom Lord 5 days ago
Very tight lipped on the data. Just that they are encouraged by what they are seeing but I would expect them to say that regardless of what is happening with the trial.
👍️ 1
ShadowHaven59 ShadowHaven59 5 days ago
Thank you
👍️0
learningcurve2020 learningcurve2020 5 days ago
I never imagined a one trick pony biotech could put out a fresh 10q and forget to update their shareholders on the trial.  Seems impossible.  
👍️0
CorsairNavigator20 CorsairNavigator20 5 days ago
Were you able to ask about data subsets. My line of conjecture would be they saw a commonality in patients with good outcomes, approached the FDA to narrow the indication and had to increase sample size. Only positive reason why it's taking forever. Yes that will really change the future of this company. Just trying to keep a positive spin. Were you able to get them to talk data at all or tell you it is going to be the greatest thing since sliced bread.
👍️0
learningcurve2020 learningcurve2020 5 days ago
If the treatment is showing good efficacy it should be a cinch to enroll such small numbers.  So it begs the question, why would they sabotage their own company? 
👍️0
learningcurve2020 learningcurve2020 5 days ago
Not a good sign for Marker, IMO.  Should've been Marker not Kalaris.  Nobody wants to talk about here, of course. 

https://www.biopharmadive.com/news/allovir-kalaris-reverse-merger-retina-diseases/732385/
👍 1
Phantom Lord Phantom Lord 5 days ago
This is only partly true. They stopped the MT401 AML PII trial to refocus their efforts in AML on the OTS version of MT401. That trial was supposed to start by the end of this year but true to form the company blew right by their own timeframe. It's supposed to start first half of next year now, IIRC. Who really knows if this will end up being the right decision or not.
👍️ 2
Phantom Lord Phantom Lord 5 days ago
I'm not worried about bad data. I'm worried that management is making poor decisions in their execution of the release. Ah86 hit the nail on the head. Their problem has always been trickling out data on an inconsequential number of patients. It's great to see the CRs but when the total number of patients you're reporting on is 3, no one is going to care. They need a bigger number. I believe they know this but in my communications with the company they are very reluctant to share the enrollment numbers. That worries me. Originally the trial was supposed to enroll 37 patients. No reason it should not be fully enrolled by now at 37 patients. That being said, back in May the enrollment on clinicaltrials.gov was increased to 79. Take with that what you will. Basically, the company needs data on more patients. They gave us the data on the initial 3 as a "tease" or indicator of how the trial started but the next data release better be at least 30 patients. There is no excuse for anything less than that.
👍️ 2
ah86 ah86 5 days ago
oh i'm not missing a thing except that i'm dumbfounded that a bunch of folks would be pessimistic having sunk a ton of money in an investment.
Talk about paradox, oh my!
An alien, if given the same facts, would bet that these folks are confident of success.
👍️0
learningcurve2020 learningcurve2020 5 days ago
The market cap is now that of a promising in vitro experiment.  
👍️0
Buckboard Buckboard 5 days ago
Thanks. The thing you are missing is many of us on here would NOT walk away "with a few bucks" selling now. We're already down a ton and would lock in big losses. My theory is hope for the best because biggest losses already in even if they close shop. I am a pessimist like B Franklin so have no big hopes here.
👍️0
learningcurve2020 learningcurve2020 5 days ago
Shrugs. 
👍️0
learningcurve2020 learningcurve2020 5 days ago
Already in penny stock land with a horrible $25M market cap.  It's the small amount of shares outstanding thanks to the reverse split that's throwing you off. 
👍️0
microcapbiotech microcapbiotech 6 days ago
That definition is obvious and simple for even the most simple to comprehend. Bad data is the kind of data that gets trials CANCELED like the AML trials were.
👍️0
ah86 ah86 6 days ago
Yes, you're wrong on some fronts. This is an open label trial. You can see failure from across the Atlantic. No company as is the case with this one, can have 'bad data' and put it in the fridge.
Patience is key here. Just over 3 bucks. You may walk away with some $$ if you sell now, though I don't know your avg cost per share. But for those that are impatient, they should pray N is greater than 10 otherwise you're back to pennystock land. The stuff works but on just 3 people is apparently equivalent to 'bad data'
If they post at minimum similar results on a greater number and you may call yourself a genius for picking this ticker.
👍️ 1
ah86 ah86 6 days ago
Define bad data,and you'll answer yourself.
👍️0
learningcurve2020 learningcurve2020 6 days ago
2029
👍️0
Buckboard Buckboard 6 days ago
I may be wrong about this and PL will definitely know but it was my understanding that if they had the data collected and it was bad, they had to release that info within a few days. Otherwise, people would be still buying stock while the company withheld bad news.
👍️ 1
microcapbiotech microcapbiotech 6 days ago
This company never produced bad data?? Is that why the AML trials were canceled?? because they produced good AML data??
I guess good data is why the website went from having several trials going to just one trial now.
👍️0
ah86 ah86 6 days ago
Allow me. The data isn't bad. This company has never produced bad data. Period.
The problem has always been? wait for it, drum roll - N
You can't get heads to turn with N being 2 or 3.
And that exactly, without doubt, is what is taking this so long. And failing to provide enough of N will cause this to slip like it hit a banana peel.
👍️ 1
ShadowHaven59 ShadowHaven59 6 days ago
Phantom Lord, what is the latest date you would give this company to show the data before you would start thinking that the data is bad? thank you.
👍️0
learningcurve2020 learningcurve2020 1 week ago
So, this Marker board member pays Marker cash to buyout their manufacturing start up facility, then he becomes a contractor where Marker pays him millions quarterly for what exactly we're not sure.  The company oddly cancels all their agreements to raise cash. All as MRKR provides no update on the progress of their one trial.  Do I have that right so far?

https://markertherapeutics.com/our-company/board-of-directors/
👍 1
Phantom Lord Phantom Lord 1 week ago
Love that ignore button, lol
👍️ 5 🫣 1
ah86 ah86 1 week ago
I found the ignore button. Such a blessing!
👍️0
learningcurve2020 learningcurve2020 1 week ago
I wouldn't worry about under or over at this point, I'd worry about  stealing your IP, assuming you're a shareholder, of course.
👍️0
ShadowHaven59 ShadowHaven59 1 week ago
For what it’s worth, I emailed the company, Stating if upper management believes in the platform. They should buy some shares on the open market as a sign of confidence for the market and shareholders. I doubt anything will happen, but hey you never know. I can’t tell if the shares are under priced or overvalued. Lol.
👍️0
learningcurve2020 learningcurve2020 1 week ago
You mean when he allegedly talks to managment? Don't you think a normal shareholder would want to comment on that last 10Q having no update on the trial? 
🚫 2 ❌️ 2
travayl travayl 1 week ago
Phantom generally posts when he has information to share.
👋 1 👍️ 1
learningcurve2020 learningcurve2020 1 week ago
Phantom goes silent, of course. 
🙈 1 🙉 1
learningcurve2020 learningcurve2020 2 weeks ago
Because I do believe in this T cell tech, I'm actually more worried they're trying to slip it out the back door as we wait for something that may never come.  Feels that way. 
👍️0

Your Recent History

NASDAQ
MRKR
Marker Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Canadian Securities Exchange (CSE) Level 1 and 2

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $738.72 only $295.49